CymaBay Therapeutics, Inc. (CBAY)
CBAY Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Investigation of CymaBay Therapeutics, Inc. and Encourages Investors to Contact the Firm
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of CymaBay Therapeutics, Inc. ("CymaBay" or "the Company") (NASDAQ: CBAY). The investigation concerns whether CymaBay and certain of its officers and/or directors have violated federal securities laws.
On January 29, 2020, CymbaBay announced in a letter that its President and CEO, that it had been “working to assess all potential ways to maximize value for our shareholders, including liquidation, sale, merger, asset acquisitions, and/or continuing development of our internal programs.” Following this news, CymaBay stock dropped $0.21 per share, or over 11%, to close at $1.65 on January 30, 2020.
If you are aware of any facts relating to this investigation, or purchased CymaBay shares,you can assist this investigation by visiting contacting the firm. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.